News
MTACU
11.35
0.00%
0.00
Trisalus Life Sciences, Inc. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023
Press release · 04/11 22:33
Medtech Acquisition Corp: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Press release · 08/10/2023 21:24
Medtech Acquisition Corp: Current report
Press release · 08/09/2023 13:01
Medtech Acquisition Corp: Prospectuses and communications, business combinations
Press release · 08/09/2023 13:01
Medtech Acquisition Corp: Current report
Press release · 08/03/2023 00:01
Medtech Acquisition Corp: Prospectuses and communications, business combinations
Press release · 08/03/2023 00:01
Medtech Acquisition Corp: Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Press release · 08/03/2023 00:01
Medtech Acquisition Corp: Quarterly report
Press release · 08/02/2023 11:01
Medtech Acquisition Corp: [Amend]General statement of acquisition of beneficial ownership
Press release · 07/27/2023 22:03
Medtech Acquisition Corp: Current report
Press release · 07/21/2023 14:01
Medtech Acquisition Corp: Prospectus [Rule 424(b)(3)]
Press release · 07/19/2023 18:01
Medtech Acquisition Corp: Notice of Effectiveness
Press release · 07/19/2023 16:03
Medtech Acquisition Corp: General statement of acquisition of beneficial ownership
Press release · 07/06/2023 21:05
Medtech Acquisition Corp: Prospectuses and communications, business combinations
Press release · 07/06/2023 12:02
Medtech Acquisition Corp: Current report
Press release · 07/06/2023 12:02
Medtech Acquisition Corp: Statement of changes in beneficial ownership of securities
Press release · 07/01/2023 09:30
Medtech Acquisition Corp: Current report
Press release · 06/30/2023 22:04
Medtech Acquisition Corp: Current report
Press release · 06/22/2023 16:24
More
Webull provides a variety of real-time MTACU stock news. You can receive the latest news about Medtech Acquisition Corp through multiple platforms. This information may help you make smarter investment decisions.
About MTACU
TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.